NYSE - BOATS Real Time Price USD
Eli Lilly and Company (LLY)
1,044.13 +6.98 (+0.67%)
At close: February 2 at 4:00:02 PM EST
1,048.20 +4.07 (+0.39%)
Overnight: 11:03:35 PM EST
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Chart Range Bar
Loading chart for LLY
Chart does not reflect overnight price.
News headlines Eli Lilly is making headlines with a $3.5 billion investment in a new weight loss facility and is set to report Q4 earnings with expectations of 32.8% revenue growth. Analysts remain optimistic about the company's future despite high valuations.
Eli Lilly is making headlines with a $3.5 billion investment in a new weight loss facility and is set to report Q4 earnings with expectations of 32.8% revenue growth. Analysts remain optimistic about the company's future despite high valuations.
Updated 12m ago · Powered by Yahoo Scout
- Previous Close
1,037.15 - Open
1,037.57 - Bid 1,046.50 x 4000
- Ask 1,049.00 x 16000
- Day's Range
1,037.57 - 1,057.41 - 52 Week Range
623.78 - 1,133.95 - Volume
2,751,911 - Avg. Volume
3,443,891 - Market Cap (intraday)
936.017B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
51.28 - EPS (TTM)
20.36 - Earnings Date Feb 4, 2026
- Forward Dividend & Yield 6.23 (0.60%)
- Ex-Dividend Date Feb 13, 2026
- 1y Target Est
1,150.00
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies; and Nimbus Therapeutics, LLC for the development of novel oral treatment for obesity and other metabolic diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
www.lilly.com47,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: LLY
View More
Performance Overview: LLY
Trailing total returns as of 2/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
LLY
2.84%
S&P 500 (^GSPC)
1.91%
1-Year Return
LLY
29.69%
S&P 500 (^GSPC)
15.49%
3-Year Return
LLY
223.32%
S&P 500 (^GSPC)
66.91%
5-Year Return
LLY
456.93%
S&P 500 (^GSPC)
82.33%
Earnings Trends: LLY
View MoreAnalyst Insights: LLY
View MoreStatistics: LLY
View MoreValuation Measures
As of 1/30/2026
Market Cap
928.27B
Enterprise Value
960.86B
Trailing P/E
50.82
Forward P/E
31.55
PEG Ratio (5yr expected)
0.94
Price/Sales (ttm)
15.72
Price/Book (mrq)
39.01
Enterprise Value/Revenue
16.17
Enterprise Value/EBITDA
37.98
Financial Highlights
Profitability and Income Statement
Profit Margin
30.99%
Return on Assets (ttm)
17.60%
Return on Equity (ttm)
96.47%
Revenue (ttm)
59.42B
Net Income Avi to Common (ttm)
18.41B
Diluted EPS (ttm)
20.36
Balance Sheet and Cash Flow
Total Cash (mrq)
9.91B
Total Debt/Equity (mrq)
178.52%
Levered Free Cash Flow (ttm)
1.4B
Compare To: LLY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: LLY
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: LLY
View MoreEven on a holiday weekend, volatility exists in markets around the globe.
Even on a holiday weekend, volatility exists in markets around the globe. On Saturday, President Trump said that in February he would start charging a 10% import tax on goods from eight European countries, including Germany, France, and the U.K. He said the move was because of opposition from those countries to his desire for American control of Greenland. Some European markets fell between 1% and 2% on Monday and U.S. futures on the major indices this morning are also down between 1% and 2%. Never a dull moment. For the next couple of weeks, earnings reports will be coming fast and furious. It is very possible that the major equity indices have been stuck in neutral for the past three months in anticipation of another round of what most likely will be another "beat and raise" quarter. On Tuesday, reports come in from NFLX, IBKR, MMM, DHI, USB, and ZION; on Wednesday, from JNJ, SCHW, TRV, and HAL; on Thursday, from INTC, PG, ISRG, GE, COF, ABT, FCX, AA, and CSX; and on Friday, from SLB and CMA. We thought the S&P 500 (SPX) was working on a bullish, continuous inverse head-and-shoulders pattern. But the index has had a tough time breaking out, instead confirming the pattern. Based on the close from Friday, it's also possible that the SPX is tracing out either a bearish-ending-diagonal or a bullish-leading-diagonal formation. If we see a 1% or so loss at the open today -- and it holds -- price will confirm a breakdown from an ending diagonal. That could open the door for a several-hundred-point drop, possibly back toward the November lows near 6,500. The Nasdaq and Nasdaq 100 would complete triangles and become susceptible to revisiting their November lows. (Mark Arbeter, CMT)
Daily – Vickers Top Buyers & Sellers for 01/12/2026
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/09/2026
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/07/2026
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.